Myeloma in the Real World: What Is Really Happening?

Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequential therapies, with the goal of prolonging progression-free and overall survival and preserving organ function to enable delivery of further therapy at relapse.

Source: Clinical Lymphoma, Myeloma and Leukemia - December 25, 2016 Category: Hematology Authors: Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer Tags: Review Source Type: research